Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR. Charles Coombes, Judith M. Bliss, Lucy Kilburn et al.|The Lancet|2007Cited by 912
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis populationJ. Floege, Charles Chazot, Tilman B. Drüeke et al.|Nephrology Dialysis Transplantation|2010Cited by 478